Comparison
Orforglipron vs semaglutide
The same receptor, reached two different ways. One is a daily tablet that is not a peptide at all; the other is a weekly injection. The trade is convenience against a longer record.
Orforglipron is a small molecule, which is why it can be a tablet. Semaglutide is a peptide, and peptides are digested — its oral form needs an absorption enhancer and strict fasting, while orforglipron needs neither.
Both act on the GLP-1 receptor and produce the familiar effects: slowed gastric emptying, reduced appetite, glucose-dependent insulin release. The mechanism is not what separates them.
What separates them is form and history. Semaglutide has years of outcome data behind it. Orforglipron is newer, and its case rests on being a daily pill with no food restrictions rather than on doing anything the injection does not.
| Attribute | Orforglipron | Semaglutide |
|---|---|---|
| Molecule type | Small molecule | Peptide |
| Receptor targets | GLP-1 | GLP-1 |
| Evidence level | Approved | Approved |
| Route | Oral | Subcutaneous |
| Dosing frequency | Once daily | Once weekly |
| Half-life | About 30 hours | About 7 days |
| Food restrictions | None | None for the injection |
| Doses per year | About 365 | About 52 |
Things worth knowing
- Being a tablet is not automatically the easier option. A daily tablet is 365 decisions a year against 52, and adherence to weekly injectables has generally been the better of the two in practice.
- Not being a peptide matters for storage and supply as much as for dosing: a small molecule needs no cold chain, which changes what a shortage looks like.
- The evidence bases are not the same size. Comparing a headline weight-reduction figure from a newer programme against one with years of cardiovascular outcome data behind it compares two different kinds of claim.
Full profile
Orforglipron
The first GLP-1 pill that is a true small molecule. Approved in April 2026, and taken any time of day with no food or water restrictions.
Full profile
Semaglutide
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.
Related
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.